Poolbeg Pharma PLC (OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after announcing that Poolbeg has identified several potential candidates from its Respiratory Syncytial Virus (RSV) AI collaboration with One Three Biotech.
He also looks back on what the company achieved during 2022 and looks ahead to what investors can expect from Poolbeg in 2023.